Business
CytoSorbents to Report Q3 2019 Operating and Financial Results
MONMOUTH JUNCTION, N.J., Oct. 30, 2019 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb®
About this update from Cytosorbents Corporation
[{"type":"text","content":"MONMOUTH JUNCTION, N.J., Oct. 30, 2019 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report Q3 2019 financial results after the market close on Tuesday, November 5, 2019. \n\n \nCytoSorbents' management will host a live conference call and presentation webcast that will recount both operational and financial progress during Q3 2019 followed by a question and answer session.\nConference Call Details:Date: Tuesday, November 5, 2019Time: 4:45 PM EasternParticipant Dial-In: 877-451-6152Conference ID: 13695453Live Presentation Webcast: http://public.viavid.com/index.php?id=136487\nIt is recommended that participants dial in approximately 10 minutes prior to the start of the call. There will also be a simultaneous live webcast of the conference call that can be accessed through the following audio feed link: http://public.viavid.com/index.php?id=136487\nAn archived recording of the conference call will be available under the Investor Relations section of the Company's website at http://cytosorbents.com/investor-relations/financial-results/ \nAbout CytoSorbents Corporation (NASDAQ: CTSO)\nCytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 58 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the \"cytokine storm\" or \"cytokine release syndrome\" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. CytoSorbents is conducting its pivotal REFRESH 2-AKI trial – a multi-center, randomized controlled, clinical trial intended to support U.S. regulatory approval of CytoSorb for use in a heart-lung machine during complex cardiac surgery to reduce organ injury. CytoSorb® has been used in more than 67,000 human treatments to date.\nCytoSorbents' purification ...